FDA accepts supplemental Biologics License Application for Roche’s Columvi combination

For people with relapsed or refractory diffuse large B-cell lymphoma

Biocon celebrates 46th Founder’s Day

The celebrations began with the unveiling of the Biocon Anthem

Dr. Reddy's launches Toripalimab in India

The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR

Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality

USFDA accepts Blenrep combinations for treatment of relapsed/refractory multiple myeloma

If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse

JHU signs MoU with Ajit Isaac Foundation to bring essential palliative care services to rural India’s terminally ill

The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation

Emcure and MS Dhoni drive India’s fight against Anemia

Emcure has launched an awareness campaign to help spread the word about male anemia

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex